PMGC Holdings Inc. (ELAB) Stock Price & Analysis
PMGC Holdings Inc. (ELAB) is trading at USD 2.71, up 0.52% today, as of October 23, 2026 at 18:11 UTC (US market open; quotes may be delayed), according to Nexqual market data.
ELAB last closed at USD 2.69; today's session has ranged USD 2.71–2.76 on volume of 1,297 shares. Market capitalization is $2.19M, with a 52-week range of USD 2.59–1,537.44 (NCM). Source: Nexqual, retrieved October 23, 2026 at 19:38 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ELAB.md
Key facts (ELAB)
- Last four reported quarters (through Jun 30, 2026): revenue $2.6M, net income -$13.5M (-523.0% margin) (SEC filings).
- Analysts: None.
- Total return with dividends: 1Y -99.8% vs S&P 500 +14.4%; 5Y -100.0% vs S&P 500 +77.0%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ELAB)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $766K | $1.7M | — | $590K | $2.6M |
| Gross profit | $447K | $1.1M | — | $185K | — |
| Net income | -$1.8M | -$4.3M | -$6.2M | -$7.7M | -$13.5M |
| EPS (diluted) | -$222821.05 | -$471578.95 | — | — | — |
| Free cash flow | — | -$4.6M | -$5.5M | -$6.4M | — |
| Gross margin | 58.4% | 66.2% | — | 31.4% | — |
| Net margin | -234.9% | -251.2% | — | -1313.0% | -523.0% |
| Revenue growth | — | +123.5% | — | — | — |
| Cash + short-term investments | $1.2M | $3.3M | $4.0M | $6.0M | — |
| Total debt | — | — | — | $85K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ELAB)
P/S 0.8x · P/B 0.1x · Earnings yield -615.65%
Analysts (ELAB)
Consensus None.
Total return (dividends reinvested) (ELAB)
| 1Y (from 2025-10-23) | 5Y (from 2023-11-20) | |
|---|---|---|
| Total return | -99.8% | -100.0% |
| S&P 500 (SPY) | +14.4% | +77.0% |
| Per year | -99.8% | -99.2% |
| Volatility (annualized) | 213.0% | 176.8% |
| Max drawdown | -99.8% (Oct 2025→Oct 2026) | -100.0% (Nov 2023→Oct 2026) |
ELAB suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | AGA Precision Systems | “we are unable to expand AGA's customer base beyond its existing network of relationships, AGA's growth may be limited and” |
| Partner | Company and MOA Life Plus | “If MOA terminates the License Agreement under the terms thereunder, including, amongst other things, if we breach our” |
Quoted from the company's 10-K filed Mar 30, 2026.
ELAB customer concentration
In the period ended Jun 30, 2026, 2 direct customers each accounted for at least 10% (11.9%, 11.9%) of revenue, per the company's 10-Q filed Aug 14, 2026. The company does not name them.
ELAB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 23, 2026 at 19:38 UTC)
| Price | USD 2.71 |
|---|---|
| Change | ▲ 0.52% (up) |
| Previous Close | USD 2.69 |
| Open | USD 2.76 |
| Day Range | USD 2.71 – 2.76 |
| 52-Week Range | USD 2.59 – 1,537.44 |
| Volume | 1,297 shares |
| Market Cap | $2.19M |
| Exchange | NCM |
Technical Analysis (ELAB)
Nexqual's technical model rates ELAB "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 19:38 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.49 (oversold) |
| vs SMA50 | Below (USD 4.55) |
| MACD | -0.58 (negative) |
Analyst Ratings (ELAB)
Wall Street analysts rate ELAB "None", per Nexqual as of October 23, 2026 at 19:38 UTC.
| Consensus Rating | None |
|---|
Earnings (ELAB)
Source: Nexqual, October 23, 2026 at 19:38 UTC.
Financials & Fundamentals (ELAB)
| Total Revenue | $2.58M |
|---|---|
| Gross Margin | -20.51% |
| Operating Margin | -289.98% |
| Profit Margin | +0.00% |
| ROE | -105.22% |
| Debt / Equity | 0.85 |
| Current Ratio | 1.36 |
| Total Cash | $18.96M |
| Total Debt | $14.24M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$6.38M (-1080.5% of revenue) |
Source: Nexqual, October 23, 2026 at 19:38 UTC.
Financial Health Score (ELAB)
Nexqual rates PMGC Holdings Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 19:38 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $15M cash and investments, no debt (Mar 2026, SEC) |
| Cash Flow | Weak — FCF negative: -$6M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -105%, ROA -33.0% |
Ownership (ELAB)
| Insider Ownership | +5.61% |
|---|---|
| Institutional Ownership | +3.28% |
| Shares Outstanding | 809,579 |
| Float | 764,186 |
| Short % of Float | +3.41% |
Source: Nexqual, October 23, 2026 at 19:38 UTC.
Leadership (ELAB)
PMGC Holdings Inc. is led by Graydon Bensler C.F.A., CEO, CFO, Secretary & Director, per Nexqual as of October 23, 2026 at 19:38 UTC.
| CEO, CFO, Secretary & Director | Graydon Bensler C.F.A. |
|---|
Major Backers & Investors (ELAB)
Notable institutional backers of PMGC Holdings Inc. include Jane Street Group, LLC, Fidelity, Morgan Stanley, according to Nexqual as of October 23, 2026 at 19:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jane Street Group, LLC | 1.01% |
| Fidelity | 0.73% |
| Morgan Stanley | 0.65% |
| Citadel | 0.26% |
| Virtu Financial LLC | 0.21% |
| Xtx Topco Ltd | 0.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.63% |
| Geode Capital | 0.3% |
Source: Nexqual, October 23, 2026 at 19:38 UTC.
From PMGC Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe that the FDA will regulate part of our product candidates as a biologic drug (i.e., a biologic) through the Biologics License Application ("BLA") process under the jurisdiction of the Office of Therapeutic Products within the Center for Biologics Evaluation and Research ("CBER").
- For future product candidates, we will also confirm the appropriate approval pathway (i.e., BLA or new drug application ("NDA")) and the appropriate FDA center with regulatory oversight (i.e., CBER or the Center for Drug Evaluation and Research ("CDER")). regulated under two statutes: The Public Health Service Act PHS Act and the Federal Food, Drug, and Cosmetic Act and their implementing regulations.
- Key operational and technical features include: is competitive and includes both small niche shops and larger, vertically integrated manufacturers.
- We compete with both domestic and international packaging providers, some of which have substantially greater resources than we do. market is competitive and includes both small niche machine shops and larger, vertically integrated manufacturers.
Partnerships
- The Company aspires to either complete an IND submission in 2026, assuming it has sufficient working capital, or to enter into a collaboration with another company to do so.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 305.39 | ▼ 0.79% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.55 | ▼ 1.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14 | ▼ 0.99% |
| PRAX | Praxis Precision Medicines, Inc | USD 253.36 | ▼ 2.15% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.89 | ▼ 2.33% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.25 | ▼ 6.93% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 19:38 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt